Neurocrine price target lowered to $125 from $137 at UBS

UBS analyst Ashwani Verma lowered the firm’s price target on Neurocrine to $125 from $137 and keeps a Buy rating on the shares. Q potential Q1 miss on Ingrezza seems to be somewhat baked in and further stock action leading up to EPS may be contingent on where expectations shake-out, the analyst tells investors in a research note. The firm’s buy side conversations indicate that Neurocrine could be a short idea going into the Q1 print, with investors viewing no upside to Ingrezza print, while next pipeline read-out at year-end presents a catalyst-lull in the interim.